surmount-1 tirzepatide trial weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Gastrointestinal tolerability and weight reduction

In the landmark SURMOUNT-1 trial published in the New England Journal of Medicine (2022), tirzepatide at the 15 mg dose achieved an average weight loss of 22.5% over 72 weeks

it is simply a more convenient way to induce the same physiological trade-offs we have seen over the last several years with the shots

Adoption of GLP-1 medications has reached a significant scale, with 1.6 million adults in England, Wales, and Scotland using drugs like Mounjaro between early 2024 and early 2025, according to UCL News

We can discuss whether hormone optimization might complement your weight loss goals during your consultation

a study linked higher fiber intake to roughly a 10 percent drop in calories consumed